Substituted Oxazole Benzenesulfonamides as Potent Human β3 Adrenergic Receptor Agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 14, 2000, Pages 1531-1534

  Ok, H O ^a   Reigle, L B ^a   Candelore, M R ^a   Cascieri, M A ^a   Colwell, L F ^a   Deng, L ^a   Feeney, W P ^a   Forrest, M J ^a   Hom, G J ^a   MacIntyre, D E ^a   Strader, C D ^a   Tota, L ^a   Wang, P ^a   Wyvratt, M J ^a   Fisher, M H ^a   Weber, A E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZENESULFONAMIDE DERIVATIVE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; ISOPRENALINE; OXAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOG; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; METABOLIC DISORDER; NONHUMAN; STRUCTURE ANALYSIS;

ADRENERGIC BETA-AGONISTS; ANIMALS; DOGS; HUMANS; INDICATORS AND REAGENTS; KINETICS; MOLECULAR STRUCTURE; OXAZOLES; RECEPTORS, ADRENERGIC, BETA-3; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 0034679641     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(00)00277-8     Document Type: Article

References (16)

1. For recent reviews see: (a) Weber, A. E. Annu. Rep. Med. Chem. 1998, 33, 193.
2. (b) Dow, R. L. Exp. Opin. Invest. Drugs, 1997, 6, 1811.
3. (c) Lowell, B. B.; Flier, J. S. Annu. Rev. Med. 1997, 48, 307.
4. (d) Arch, J. R. S.; Wilson, S. Int. J. Obesity 1996, 20, 191.
5. (e) Himms-Hagen, J.; Danforth, E. Curr. Opin. Endocrin. Diabetes 1996, 3, 59.
6. (f) Claus, T. H.; Bloom, J. D. Annu. Rep. Med. Chem. 1995, 30, 189.
7. Fisher M.H., Amend A.M., Bach T.J., Barker J.M., Brady E.J., Candelore M.R., Carroll D., Cascieri M.A., Chiu S.-H.L., Deng L., Forrest M.J., Hegarty-Friscino B., Guan X.-M., Hom G.H., Hutchins J.E., Kelly L.J., Mathvink R.J., Metzger J.M., Miller R.R., Ok H.O., Parmee E.R., Saperstein R., Strader C.D., Stearns R.A., Thompson G.M., Tota L., Vicario P.P., Weber A.E., Woods J.W., Wyvratt M.J., Zafian P.T., MacIntyre D.E. J. Clin. Invest. 101:1998;2387.
8. Parmee E.R., Naylor E.M., Perkins L., Colandrea V.J., Ok H.O., Candelore M.R., Cascieri M.A., Deng L., Feeney W.P., Forrest M.J., Hom G.J., MacIntyre D.E., Miller R.R., Stearns R.A., Strader C.D., Tota L., Wyvratt M.J., Fisher M.H., Weber A.E. Bioorg. Med. Chem. Lett. 9:1999;749.
9. Naylor E.M., Parmee E.R., Colandrea V.J., Perkins L., Candelore M.R., Cascieri M.A., Colwell L.F., Deng L., Feeney W.P., Forrest M.J., Hom G.J., MacIntyre D.E., Strader C.D., Tota L., Wang P., Wyvratt M.J., Fisher M.H., Weber A.E. Bioorg. Med. Chem. Lett. 9:1999;775.
10. Naylor E.M., Colandrea V.J., Candelore M.R., Cascieri M.A., Colwell L.F. Jr., Deng L., Feeney W.P., Forrest M.J., Hom G.J., MacIntyre D.E., Strader C.D., Tota L., Wang P.-R., Wyvratt M.J., Fisher M.H., Weber A.E. Bioorg. Med. Chem. Lett. 8:1998;3089.
11. Graham S.L., Hoffman J.M., Gautheron P., Michelson S.R., Scholz T.H., Shepard K.L., Smith A.M., Smith R.L., Sondey J.M., Sugrue M.F. J. Med. Chem. 33:1990;749.
12. With 1 equiv of NBS, bromine was introduced exclusively at the 5-position of the oxazole.
13. All final compounds were characterized by NMR, MS, and HPLC.
14. 3 AR was obtained from Professor J. Granneman (Wayne State University), Granneman, J. G.; Lahners, K. N.; Rao, D. D. Mol. Pharmacol. 1992, 42, 964.
15. 2 ARs were cloned as described in Frielle, T.; Collins, S.; Daniel, K. W.; Caron, M. G.; Lefkowitz, R. J.; Kobilka, B. K. Proc. Natl. Acad. Sci. USA 1987, 84, 7920 and
16. 125I-cyanopindolol binding, respectively.